Calidi Biotherapeutics (CLDI) Other Non-Current Liabilities (2021 - 2025)
Calidi Biotherapeutics' quarterly Other Non-Current Liabilities came in at $115000.0 in Q4 2025, down 10.16% year-on-year from $128000.0 in Q4 2024, and down 42.79% quarter-over-quarter from $201000.0 in Q3 2025.
Calidi Biotherapeutics has reported Other Non-Current Liabilities for 5 years, with the latest figure at $115000.0 in Q4 2025.
- For the quarter ending Q4 2025, Other Non-Current Liabilities fell 10.16% year-over-year to $115000.0; the trailing twelve-month figure through Dec 2025 stood at $115000.0 (down 10.16% YoY), and the FY2025 full-year result was $115000.0, down 10.16% from the prior year.
- Other Non-Current Liabilities for Q4 2025 stood at $115000.0, down from $201000.0 in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $30.3 million in Q4 2022, with the low at $50000.0 in Q2 2024.
- Average Other Non-Current Liabilities over 5 years is $3.1 million, with a median of $647000.0 recorded in 2024.
- Year-over-year, Other Non-Current Liabilities jumped 306.23% in 2022 and tumbled 97.95% in 2023.
- Tracing CLDI's Other Non-Current Liabilities over 5 years: stood at $7.5 million in 2021, then jumped by 306.23% to $30.3 million in 2022, then plunged by 97.95% to $623000.0 in 2023, then tumbled by 79.45% to $128000.0 in 2024, then fell by 10.16% to $115000.0 in 2025.
- The last three Other Non-Current Liabilities figures came in at $115000.0 (Q4 2025), $201000.0 (Q3 2025), and $96000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn |
| 10 | Calidi Biotherapeutics | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 115,000.00 |
| Sep 30, 2025 | 201,000.00 |
| Jun 30, 2025 | 96,000.00 |
| Mar 31, 2025 | 81,000.00 |
| Dec 31, 2024 | 128,000.00 |
| Sep 30, 2024 | 176,000.00 |
| Jun 30, 2024 | 50,000.00 |
| Mar 31, 2024 | 647,000.00 |
| Dec 31, 2023 | 623,000.00 |
| Sep 30, 2023 | 2.95 Mn |
| Jun 30, 2023 | 1.94 Mn |
| Mar 31, 2023 | 656,500.00 |
| Dec 31, 2022 | 30.34 Mn |
| Sep 30, 2022 | 885,000.00 |
| Jun 30, 2022 | 1.35 Mn |
| Mar 31, 2022 | 5.37 Mn |
| Dec 31, 2021 | 7.47 Mn |